Newsroom

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Globant S.A. (NYSE: GLOB) common stock between February 15, 2024 and August 14, 2025, inclusive (the “Class Period”). Globant is an international technology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Globant S.A...

PLANO, Texas--(BUSINESS WIRE)--Sally Beauty Holdings, Inc. (NYSE:SBH) (the “Company”), the leader in professional hair color, announced today that it will host a conference call and webcast on May 11, 2026, at 7:30 a.m. Central Time, to discuss its second quarter financial results. A copy of the press release announcing the second quarter financial results is expected to be made available on May 11, 2026, before the U.S. financial markets open on the Company's website sallybeautyholdings.com/in...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired SES AI Corporation (NYSE: SES) securities between January 29, 2025 and March 4, 2026. SES claims to be a "leading developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (“Li-Metal”) and Lithium-ion (“Li-ion”) rechargeable battery technologies and battery materials for Energy Storage Systems (“ESS”), Urban Air Mobility (“UAM”)...

NEW YORK--(BUSINESS WIRE)--Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann”), a leading middle-market investment bank providing investment banking, equity research, and institutional sales and trading services, today announced that Aydin Huseynov, M.D., CFA, has joined the firm's Healthcare Investment Banking Group as Managing Director, Biotechnology Investment Banking Specialist. Dr. Huseynov will focus on the continued expansion of Ladenburg's biotechnology investment banking platform...

DALLAS--(BUSINESS WIRE)--CBRE Group, Inc. (NYSE:CBRE) (the “Company”) today announced the pricing of the offering of $750,000,000 aggregate principal amount of 5.250% Senior Notes due 2036 (the “Notes”). The Notes will have an interest rate of 5.250% per annum and are being issued at a price equal to 98.947% of their face value. The Company’s wholly owned subsidiary, CBRE Services, Inc. (“Services”), will issue the Notes, which will be guaranteed on a full and unconditional basis by the Company...

LOS ANGELES--(BUSINESS WIRE)--AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities...

NEW YORK--(BUSINESS WIRE)--KBRA is pleased to announce the assignment of preliminary ratings to 15 classes of Benchmark 2026-B43, a $683.2 million CMBS conduit transaction collateralized by 31 commercial mortgage loans secured by 53 properties. The collateral properties are located throughout 26 MSAs, of which the three largest are New York (20.2% of pool balance), Washington - NoVA - MD (12.1%), and Cleveland (7.9%). The pool has exposure to all major property types, with four types representi...

FILADÉLFIA--(BUSINESS WIRE)--A PCI Pharma Services (“PCI”) – uma organização global integrada de desenvolvimento e fabricação por contrato (CDMO) líder mundial, focada em terapias inovadoras de moléculas pequenas e biológicas – anunciou uma série de grandes investimentos em infraestrutura que aprofundam substancialmente suas capacidades de envase estéril e administração avançada de medicamentos. À medida que os fabricantes farmacêuticos e seus parceiros de desenvolvimento priorizam cada vez mai...

費城--(BUSINESS WIRE)--(美國商業資訊)-- PCI Pharma Services (“PCI”)是一家世界首屈一指的整合式全球委託開發和製造機構(CDMO)，專注于創新生物製劑和小分子療法。該公司宣布了一系列重大基礎設施投資，大幅深化其無菌充填完成和先進藥物傳輸能力。隨著製藥企業及其開發合作夥伴日益重視美國供應鏈韌性，PCI的最新投資是這家CDMO在美國和歐洲業務逾10億美元整體規劃的一部分，強化了其從臨床階段到商業上市，為藥品開發和生產、臨床試驗供應以及藥械組合組裝提供順暢支援的能力——所有這一切都以全球產能、技術專長、深厚的科學知識以及業界首屈一指的品質和監管記錄為後盾。 PCI投資計畫的核心是其聖地牙哥園區的一個1億美元專案，該專案將建設一條用於即用型(RTU)預充填針筒和藥筒的高速隔離器充填線。該生產線計畫於2028年上半年運行，將使該園區現有的針筒和藥筒充填產能增加一倍以上。這將是PCI在聖地牙哥的第二條隔離器充填完成生產線，目前該園區支援和生產超過45種經美國食品藥物管理局(FDA)核准的產品。該園區還具備預充填針筒和藥筒規模化無菌充填能力，可專業承接...

费城--(BUSINESS WIRE)--(美国商业资讯)-- PCI Pharma Services (“PCI”)是一家世界领先的一体化全球合同开发和制造组织(CDMO)，专注于创新生物制剂和小分子疗法。该公司宣布了一系列重大基础设施投资，大幅深化其无菌灌封和先进药物输送能力。随着制药企业及其开发合作伙伴日益重视美国供应链韧性，PCI的最新投资是这家CDMO在美国和欧洲业务逾10亿美元整体规划的一部分，强化了其从临床阶段到商业上市，为药品开发和生产、临床试验供应以及药械组合组装提供无缝支持的能力——所有这一切都以全球产能、技术专长、深厚的科学知识以及行业领先的质量和监管记录为后盾。 PCI投资计划的核心是其圣迭戈园区的一个1亿美元项目，该项目将建设一条用于即用型(RTU)预充式注射器和卡式瓶的高速隔离器灌装线。该生产线计划于2028年上半年投入运营，将使该园区现有的注射器和卡式瓶灌装产能增加一倍以上。这将是PCI在圣迭戈的第二条隔离器灌封生产线，目前该园区支持和生产超过45种经美国食品药品管理局(FDA)批准的产品。该园区还具备预充式注射器和卡式瓶规模化无菌灌装能力，可专业承接寡核...